Cash Falls to $32.3M as Q3 Net Loss Widens to $21.2M; ELAINE-3 Enrollment Slips to 4Q 2026
LONA sits 46% above its 52-week low of $2.21 on light trading volume (0.3× avg).
Summary
LeonaBio ended September with $32.3M in cash, cash equivalents and investments, down from $88.3M at December 31, 2025, while burning $18.98M in operations during the quarter. R&D spending jumped to $14.6M from $2.8M a year earlier on ELAINE-3 trial costs, pushing the net loss to $21.2M, or $0.89 per share. The company now says it will complete ELAINE-3 enrollment in 4Q 2026, with topline data not expected until 2H 2027 — a long gap for a company this size. That cash balance is thin against the current burn rate, and the prior 10-Q already carried a going concern warning; the 23M Series A warrants that became exercisable in September could bring in up to $146.2M if exercised, which is now the key funding lever. Watch warrant exercise activity and any financing announcement before the cash runs down.
At the time of this announcement, LONA was trading at $3.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $30.4M. The 52-week trading range was $2.21 to $14.21. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.